BioCentury
ARTICLE | Company News

Merck pharmaceuticals news

December 15, 2008 8:00 AM UTC

The pharma formed Merck BioVentures to develop follow-on biologics (FOBs). The first candidate in development is MK-2578, a pegylated erythropoietin (EPO) in Phase I testing for anemia, with a launch ...